DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/h9gmk2/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bone Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
Companies Involved:
- APT Therapeutics, Inc.
- Alethia Biotherapeutics Inc.
- AlphaMab Co., Ltd
- Amgen Inc.
- Amura Holdings Ltd.
- Bayer AG
- Celsion Corporation
- Debiopharm International S.A.
- Deciphera Pharmaceuticals, LLC
- DexTech Medical AB
- Digna Biotech, S.L.
- Eli Lilly and Company
- Johnson & Johnson
- Medivir AB
- Merrion Pharmaceuticals Plc
- Osteologix Holdings Plc.
- Sigma-Tau S.p.A.
- TWi Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
-
Transgene SA
Drug Profiles:
- denosumab
- radium Ra 223 dichloride
- zoledronic acid
- MLN-1202
- doxorubicin liposomal
- radium Ra 223 dichloride
- Osteodex
- MIV-711
- Debio-0719
- P-17
- disitertide
- MIV-710
- SST-0001
- TG-3003
- AB-25E9
- AM-3701
- DCC-2909
- AC-301
- APT-102
- Secreted Phosphoprotein 24 KDa
- Vicrostatin
- ADM-01
- JNJ-28312141
- DP-6865
- LY-2109761
- LY-364937
- EGFR Inhibitors for Oncology
- (paclitaxel + PEG + alendronate)
For more information visit http://www.researchandmarkets.com/research/h9gmk2/bone_metastasis
